Abstract Number: 0211 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs
Background/Purpose: This Phase 3, randomized, double-blind, placebo (PBO)-controlled study assessed the efficacy and safety of upadacitinib (UPA) in combination with csDMARDs in patients with rheumatoid…Abstract Number: 0228 • ACR Convergence 2020
Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
Background/Purpose: In the randomized, double-blinded, Phase 3 SELECT-COMPARE study, upadacitinib (UPA) + MTX demonstrated greater clinical and functional responses vs adalimumab (ADA) + MTX in…Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…Abstract Number: 0488 • ACR Convergence 2020
Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database
Background/Purpose: There is growing interest regarding the role of neuroinflammation in the development of dementia and the potential role for anti-inflammatory therapy, including TNF-inhibitors (TNFi),…Abstract Number: 0635 • ACR Convergence 2020
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…Abstract Number: 0753 • ACR Convergence 2020
Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort
Background/Purpose: Rheumatoid arthritis is a heterogeneous disease with different clinical presentation and prognostic factors including the immune process in the synovium. The development of ultrasound-guided…Abstract Number: 0770 • ACR Convergence 2020
Effect of Citrullination on the Processing and Presentation of Rheumatoid Arthritis Autoantigens
Background/Purpose: Citrullinated proteins are hallmark targets of the autoimmune response in rheumatoid arthritis (RA), but the mechanism by which immune tolerance is broken to these self-proteins…Abstract Number: 0787 • ACR Convergence 2020
MerTK Synovial Expression Correlates with Disease Activity and Treatment Response in Rheumatoid Arthritis Patients
Background/Purpose: Despite valuable improvements in long-term clinical outcomes, a significant portion of rheumatoid arthritis (RA) patients still do not adequately respond to available treatments, and…Abstract Number: 0804 • ACR Convergence 2020
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…Abstract Number: 0821 • ACR Convergence 2020
Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and is more frequent and severe in women than in men. Symptom severity, disease progression,…Abstract Number: 0949 • ACR Convergence 2020
SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation
Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…Abstract Number: 1002 • ACR Convergence 2020
Prostate Cancer Risk Is Not Increased in Rheumatoid Arthritis After Accounting for Retention in a Health Care System
Background/Purpose: Patients with rheumatoid arthritis (RA) may have up to a 15% increased risk of prostate cancer per a recent meta-analysis (Simon et al. Arthritis…Abstract Number: 1018 • ACR Convergence 2020
Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)
Background/Purpose: Treat-to-Target(T2T) is the main therapeutic strategy for patients with RA and SLE. There has been no report on comparation of seasonal variations on T2T…Abstract Number: 1189 • ACR Convergence 2020
Serum High-sensitive Cardiac Troponin at Baseline Predict Cardiovascular Events in Rheumatoid Arthritis and Osteoarthritis
Background/Purpose: In rheumatoid arthritis (RA), excess mortality and inflammation has been attributed to cardiovascular (CV) diseases. High-sensitivity cardiac troponins (hscTnT) allow measurement of cardiac troponin…Abstract Number: 1205 • ACR Convergence 2020
Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular (CV) disease. The treatment of arthritis by tumour necrosis factor α (TNF-α)…
- « Previous Page
- 1
- …
- 148
- 149
- 150
- 151
- 152
- …
- 188
- Next Page »